4//SEC Filing
CorMedix Inc. 4
Accession 0001638599-16-001038
$CRMDCIK 0001410098operating
Filed
Jun 5, 8:00 PM ET
Accepted
Jun 6, 5:34 PM ET
Size
19.6 KB
Accession
0001638599-16-001038
Insider Transaction Report
Form 4
CorMedix Inc.CRMD
Duffy Matthew
Director
Transactions
- Sale
Common Stock, $0.001 par value per share
2016-06-03$2.73/sh−46,106$126,008→ 28,571 total
Holdings
- 100,000
Stock Option (right to buy)
Exercise: $0.90Exp: 2023-03-20→ Common Stock, $0.001 par value per share (100,000 underlying) - 125,000
Stock Option (right to buy)
Exercise: $0.68Exp: 2022-12-05→ Common Stock, $0.001 par value per share (125,000 underlying) - 50,000
Stock Option (right to buy)
Exercise: $5.62Exp: 2025-03-01→ Common Stock, $0.001 par value per share (50,000 underlying) - 15,000
Stock Option (right to buy)
Exercise: $0.28Exp: 2021-11-21→ Common Stock, $0.001 par value per share (15,000 underlying) - 594
Phantom Stock
Exercise: $0.00→ Common Stock, $0.001 par value per share (594 underlying) - 75,000
Stock Option (right to buy)
Exercise: $1.91Exp: 2026-02-21→ Common Stock, $0.001 par value per share (75,000 underlying) - 150,000
Stock Option (right to buy)
Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (150,000 underlying) - 30,000
Stock Option (right to buy)
Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (30,000 underlying) - 5,000
Stock Option (right to buy)
Exercise: $0.29Exp: 2022-01-06→ Common Stock, $0.001 par value per share (5,000 underlying) - 1,653
Phantom Stock
Exercise: $0.00→ Common Stock, $0.001 par value per share (1,653 underlying) - 1,153
Phantom Stock
Exercise: $0.00→ Common Stock, $0.001 par value per share (1,153 underlying)
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.67 to $2.77, inclusive.
- [F2]These options vested 100% on January 10, 2014.
- [F3]These options vest in full on the first anniversary of the date of grant.
- [F4]These options vest quarterly over two years.
- [F5]These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- [F6]The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
- [F7]Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a directo
Documents
Issuer
CorMedix Inc.
CIK 0001410098
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001410098
Filing Metadata
- Form type
- 4
- Filed
- Jun 5, 8:00 PM ET
- Accepted
- Jun 6, 5:34 PM ET
- Size
- 19.6 KB